Home
News
默认头像

Silo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia University

2024-06-07MyfxbookMyfxbook
Biopharmaceutical company Silo Pharma, Inc. (SILO) announced Wednesday that it has exercised its option to license Alzheimer's disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research
Silo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia University

(RTTNews) - Biopharmaceutical company Silo Pharma, Inc. (SILO) announced Wednesday that it has exercised its option to license Alzheimer's disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021.

Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement.

The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024.

The global Alzheimer's disease therapeutics market size is forecasted to exceed $30.8 billion by 2033, with a CAGR of 18.8% from 2024 to 2033.

Disclaimers

The article is sourced from Myfxbook with the original source credited. The views expressed herein are not affiliated with FXOR; readers are encouraged to approach the content rationally. Copyright belongs to the original author. If unintentional infringement upon media or personal intellectual property rights has occurred, please contact us, and we will promptly remove the content. FXOR merely provides information storage services. The article is compiled and released by FXOR; reprints must indicate the original source.

Myfxbook Enter the brand column

Hottest

About 1 Year Ago

European stocks closed lower on Thursday on concerns the Federal Reserve might not reduce interest rates more than one time this year despite soft consumer price and producer price inflation data.

About 1 Year Ago

John Wiley & Sons, Inc. (WLY) reported Thursday net income for the first quarter of $25.27 million or $0.46 per share, sharply lower than $68.34 million or $1.22 per share in the prior-year quarter.

About 1 Year Ago

Asian stocks rose broadly on Thursday as soft U.S. inflation data helped keep the door open for a Federal Reserve rate cut in September.

About 1 Year Ago

While announcing its widely expected decision to leave interest rates unchanged on Wednesday, the Federal Reserve also revealed officials now expect only one interest rate cut this year. In support of its goals of

About 1 Year Ago

Asian stocks drifted lower on Wednesday as investors awaited key U.S. inflation data as well as a Federal Reserve policy decision later in the day for additional clues on the outlook for interest rates.

home

Home

home

Brokers

home

News

home

Expo

home

Mine